Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.

Author(s): Launay O, Gerard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Levy C, Rivet S, Jacomet C, Aboulker JP, Yeni P, Agence Nationale de Recherches sur le SIDA (ANRS) 081 Study Group

Affiliation(s): Service de Maladies Infectieuses et Tropicales, Hopital Bichat-Claude Bernard, Paris, France. odile.launay@avc.ap-hop-paris.fr

Publication date & source: 2002-11-01, Clin Infect Dis., 35(9):1096-105. Epub 2002 Oct 15.

Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial

We compared use of a 3-class regimen (nevirapine [Nvp], stavudine [d4T], and indinavir [Idv; 1000 mg 3 times daily]) with use of a 2-class regimen (lamivudine [3TC], d4T, and Idv [800 mg 3 times daily]) for 145 patients infected with human immunodeficiency virus type 1 (HIV-1). At week 72, the plasma HIV-1 RNA level was undetectable in 52% of Nvp recipients versus 79% of 3TC recipients (P<.001). Idv trough levels were 81 ng/mL in the Nvp group and 99 ng/mL in the 3TC group (P=.012). In the Nvp group, 42.5% of patients discontinued the study regimen; in the 3TC group, 22.5% of patients discontinued therapy (P=.013). The rate of resistance to nonnucleoside analogue reverse-transcriptase inhibitors among patients in the Nvp group with virological failure was not different from the rate of resistance to 3TC among patients in the 3TC group with virological failure. These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues.